COSCIENS Biopharma Inc.
CSCI.TO
TSX
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 19.08% | -46.05% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 19.08% | -46.05% | |||
| Cost of Revenue | 23.35% | -47.15% | |||
| Gross Profit | 11.74% | -44.05% | |||
| SG&A Expenses | 14.14% | -20.33% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 16.49% | -30.11% | |||
| Operating Income | -14.64% | 11.47% | |||
| Income Before Tax | -19.46% | 32.63% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -20.01% | 32.65% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -20.01% | 32.65% | |||
| EBIT | -14.64% | 11.47% | |||
| EBITDA | -148.33% | 13.07% | |||
| EPS Basic | -139.25% | 32.70% | |||
| Normalized Basic EPS | -174.34% | 41.56% | |||
| EPS Diluted | -139.25% | 32.70% | |||
| Normalized Diluted EPS | -174.34% | 41.56% | |||
| Average Basic Shares Outstanding | 100.65% | 0.08% | |||
| Average Diluted Shares Outstanding | 100.65% | 0.08% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||